WuXi Biologics is trading HK$50.30, up +4.10%, with no confirmed company-specific catalyst identified for the November 5 move; available context points to broader Hong Kong innovative-drug stock strength on November 4.
- WuXi Biologics announced a Fresenius biosimilars development agreement on November 2; available reporting does not establish it as the cause of this move.
- The quoted price and change are from the provided price context.